Uterine myxoid leiomyosarcoma and CYVADIC-etoposide therapy

Int J Gynaecol Obstet. 1994 Sep;46(3):321-4. doi: 10.1016/0020-7292(94)90413-8.

Abstract

Objectives: To conduct a pathological characterization of rare uterine myxoid leiomyosarcoma (MLS) and establish an effective chemotherapy for metastasis after hysterectomy.

Methods: Histological and immunohistochemical methods were used to characterize the type of uterine MLS in a 39-year-old female. For multiple lung metastases found 3 months after operation, CYVADIC (400 mg cyclophosphamide, 1 mg vincristine, 50 mg epirubicin and 400 mg dacarbazine per body for one course) and oral etoposide (50 mg/body per day for 2 weeks) were applied.

Results: The rapidly enlarging uterine tumors exhibited gelatinous cut surfaces, a high count of 30 mitotic cells per 10 hpf and mucinous stroma, indicating a rare high-mitotic type of uterine MLS. The two-course CYVADIC-etoposide therapy was effective for disseminated pulmonary metastases.

Conclusion: The present MLS was a rare high-mitotic type. CYVADIC-etoposide was an optional effective chemotherapy for lung metastasis in this case.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Dacarbazine / administration & dosage
  • Epirubicin / administration & dosage
  • Etoposide / administration & dosage
  • Fatal Outcome
  • Female
  • Humans
  • Hysterectomy
  • Immunohistochemistry
  • Leiomyosarcoma / diagnosis
  • Leiomyosarcoma / drug therapy*
  • Leiomyosarcoma / secondary*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary*
  • Mitotic Index
  • Treatment Outcome
  • Uterine Neoplasms / pathology*
  • Uterine Neoplasms / surgery
  • Vincristine / administration & dosage

Substances

  • Epirubicin
  • Vincristine
  • Etoposide
  • Dacarbazine
  • Cyclophosphamide